Study Evaluating Etanercept in Patients With Rheumatoid Arthritis(RA), Juvenile Idiopathic Arthritis (JIA), or Psoriatic Arthritis (PsA) in Spain

Wyeth

Status: Completed

Conditions: Arthritis, Psoriatic; Arthritis, Rheumatoid

Treatments: Drug: Etanercept

Study type: Observational

Funder types: Industry

Identifiers

NCT00195377

101393

Details and patient eligibility

About

The purpose of this study is to assess the safety of etanercept in patients with rheumatoid arthritis (RA), juvenile idiopathic arthritis (JIA) or psoriatic arthritis (PsA) in Spain

Sex: All

Ages: 4+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• RA or PsA in whom DMARDs/antiTNF antibodies/anti IL1 has been insufficient or inappropriate
• Children from 4 to 17 years old with JIA polyarticular

Exclusion criteria

• Clinically significant abnormal screening lab values
• Patients who are planning to undergo elective surgery during the study period.
• Other current autoimmune connective tissue diseases